Timing of relapses in multiple sclerosis is one of several interactions among aging, the trajectory of progressive disease, and worsening disability, according to Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at the Mayo Clinic.
Timing of relapses in multiple sclerosis is one of several interactions among aging, the trajectory of progressive disease, and worsening disability, according to Burcu Zeydan, MD, assistant professor of neurology, assistant professor of radiology, at the Mayo Clinic.
Transcript
How does aging impact multiple sclerosis?
We know that there are several aging-associated observations in multiple sclerosis (MS). These observations are likely to contribute to many aspects of the illness, such as clinical and subclinical activity, recovery from relapses, progressive MS onset, [central nervous system] CNS reserve and aging-related changes in the immune system, including immunomodulation. First of all, the postrelapse clinical potential significantly declines with aging. Patients whose first-ever relapses happened earlier in life recover better than those whose first several relapses happen later in life. We also showed that when the first and last several relapses within the same individual are compared, the postrelapse curing potential declines with aging, leading to a greater disability accumulation due to relapses. Another important aging-related observation is the time of transition from the relapsing-remitting phase to the progressive phase in MS. As about 80% of the patients ultimately evolve to the progressive phase of the disease, it is important to point out that the progressive MS onset seems to be age dependent. We have shown in the past that evolution from the relapsing-remitting phase to the progressive phase usually happens during the fifth decade with mean age of 45 plus or minus 10 years. The structural central nervous system reserve is also expected to decrease with aging both in the general population and also in patients with MS. And the imaging studies showed that the white matter maturation terminates by the fourth decade, but it starts to decline afterwards. And we think that this might be relevant to the decline of postrelapse recovery potential in all the patients, and also might be relevant to the transition to the progressive phase, which is expected to happen during the fifth decade. We also observe that relapses and subclinical lesions become less common with aging in patients with MS. However, it is still important to prevent relapses in older individuals because even a single relapse at an older age may significantly contribute to the disability worsening. This is likely due to the lower postrelapse recovery potential and higher propensity for progressive disease with aging. It is also important in making decisions about treatment discontinuation in older adults with illness. So overall, aging seems to be the major determinant of clinical evolution in multiple sclerosis.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment
April 4th 2025Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.
Read More